BPI-2358-105:A Phase 2/3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)

February 19, 2019
https://clinicaltrials.gov/ct2/results?id=NCT03102606
Cancer - Genitourinary/ Prostate
Cancer, Phase II, Phase 2, Phase 3, Phase III, Chemotherapy induced neutropenia, Solid Tumors, Protective 1
Completed